IDEXX Laboratories Inc banner

IDEXX Laboratories Inc
XBER:IX1

Watchlist Manager
IDEXX Laboratories Inc Logo
IDEXX Laboratories Inc
XBER:IX1
Watchlist
Price: 581.4 EUR
Market Cap: €48.3B

Wall St Price Targets

IX1 Price Targets Summary
IDEXX Laboratories Inc

Wall Street analysts forecast IX1 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IX1 is 766.02 EUR with a low forecast of 505.79 EUR and a high forecast of 894.87 EUR.

Lowest Forecast
Price Target
505.79 EUR
13% Downside
Average Forecast
Price Target
766.02 EUR
32% Upside
Highest Forecast
Price Target
894.87 EUR
54% Upside
IDEXX Laboratories Inc Competitors:
Price Targets
SITM
SiTime Corp
22% Upside
TEL
TE Connectivity Ltd
33% Upside

Revenue
Forecast

10% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
10% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 3 years is 10%.

Gross Profit
Forecast

11% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
11% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 3 years is 11%.

Operating Income
Forecast

14% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
14% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 14%. The projected CAGR for the next 3 years is 12%.

Pre-Tax Income
Forecast

13% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
13% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 13%. The projected CAGR for the next 3 years is 13%.

Net Income
Forecast

15% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
15% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 15%. The projected CAGR for the next 3 years is 12%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is IX1's stock price target?
Price Target
766.02 EUR

According to Wall Street analysts, the average 1-year price target for IX1 is 766.02 EUR with a low forecast of 505.79 EUR and a high forecast of 894.87 EUR.

What is the Revenue forecast for IDEXX Laboratories Inc?
Projected CAGR
10%

Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 3 years is 10%.

What is the Gross Profit forecast for IDEXX Laboratories Inc?
Projected CAGR
11%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 3 years is 11%.

What is the Operating Income forecast for IDEXX Laboratories Inc?
Projected CAGR
12%

Over the last 13 years, the compound annual growth rate for Operating Income has been 14%. The projected CAGR for the next 3 years is 12%.

What is the Pre-Tax Income forecast for IDEXX Laboratories Inc?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 13%. The projected CAGR for the next 3 years is 13%.

What is the Net Income forecast for IDEXX Laboratories Inc?
Projected CAGR
12%

Over the last 13 years, the compound annual growth rate for Net Income has been 15%. The projected CAGR for the next 3 years is 12%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett